Lilo is an evidence-based companion app that helps
patients with metabolic syndrome or in cancer remission to adapt their behaviors, using health
psychology, AI, and innovative behavioral nudges.
Pharmaceutical companies in cardiovascular health and oncology can leverage on the Lilo Engine to develop their own prescribed digital therapeutic solution for faster market access, increase medication adherence, and collect real-world evidence and treatment adherence through innovative remote blood testing.
All modules within the journeys are built based on clinical evidence and real patient feedback, with a community of over 3,000 patients and a total of over 60 different reported comorbidities